China Dasheng Biotechnology Company
China Dasheng Biotechnology Company Fundamental Analysis
China Dasheng Biotechnology Company (CDBT) shows moderate financial fundamentals with a PE ratio of -35.70, profit margin of 0.00%, and ROE of 14.61%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 62.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CDBT's fundamental strength across five key dimensions:
Efficiency Score
WeakCDBT struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCDBT trades at attractive valuation levels.
Growth Score
WeakCDBT faces weak or negative growth trends.
Financial Health Score
ModerateCDBT shows balanced financial health with some risks.
Profitability Score
WeakCDBT struggles to sustain strong margins.
Key Financial Metrics
Is CDBT Expensive or Cheap?
P/E Ratio
CDBT trades at -35.70 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CDBT's PEG of -1.39 indicates potential undervaluation.
Price to Book
The market values China Dasheng Biotechnology Company at -5.42 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -32.32 times EBITDA. This is generally considered low.
How Well Does CDBT Make Money?
Net Profit Margin
For every $100 in sales, China Dasheng Biotechnology Company keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.61 in profit for every $100 of shareholder equity.
ROA
China Dasheng Biotechnology Company generates $-27.32 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
CDBT converts -1.43% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-35.70
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.39
vs 25 benchmark
P/B Ratio
Price to book value ratio
-5.42
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-1.45
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.10
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.15
vs 25 benchmark
ROA
Return on assets percentage
-0.27
vs 25 benchmark
ROCE
Return on capital employed
0.15
vs 25 benchmark
How CDBT Stacks Against Its Sector Peers
| Metric | CDBT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -35.70 | 19.09 | Better (Cheaper) |
| ROE | 14.61% | 842.00% | Weak |
| Net Margin | 0.00% | 3730.00% | Weak |
| Debt/Equity | -1.45 | 0.89 | Strong (Low Leverage) |
| Current Ratio | 0.10 | 660.25 | Weak Liquidity |
| ROA | -27.32% | -24785.00% (disorted) | Weak |
CDBT outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews China Dasheng Biotechnology Company's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical